Medicinal plants are an important source of bioactive compounds that have various biological effects on pests and diseases of agricultural and livestock importance. The present study evaluated the nematicidal and insecticidal effects of the acetone extract (E-Ac) of Prosopis laevigata leaves. The tests were carried out under in vitro conditions. E-Ac had 100% nematicidal activity against Haemonchus contortus at 40 and 20 mg/mL, while at 10 mg/mL it had nearly 60% mortality against L3 H. contortus larvae. When E-Ac was incorporated into an artificial diet, it had an 88% insecticidal effect against Melanaphis sorghi at 72 h at 10 mg/mL. The phytochemical profile of E-Ac revealed the presence of alkaloids, flavonoids, coumarins, tannins, sterols/terpenes and saponins. The results of the present study reveal that E-Ac has secondary metabolites with anthelmintic activity against L3 larvae of H. contortus and insecticidal activity against adults of M. sorghi, which could represent a viable and affordable allelopathic tool in the control of gastrointestinal nematodiasis in small ruminants and against aphids of agricultural importance.

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has produced a serious emergency for global public health, placing enormous stress on national health systems in many countries. Several studies suggest that cytokine storms (interleukins) may play an important role in severe cases of COVID-19. Neutralizing key inflammatory factors in cytokine release syndrome (CRS) could therefore be of great value in reducing the mortality rate. Tocilizumab (TCZ) in its intravenous (IV) form of administration-RoActemra? 20 mg/mL (Roche)-is indicated for treatment of severe CRS patients. Preliminary in-vestigations have concluded that inhibition of IL-6 with TCZ appears to be efficacious and safe, with several ongoing clinical trials. This has led to a huge increase in demand for IV TCZ for treating severe COVID-19 patients in hospitals, which has resulted in drug shortages. Here, we present a comparability study assessing the main critical physicochemical attributes of TCZ solutions used for infusion, at 6 mg/mL and 4 mg/mL, prepared from RoActemra? 20 mg/mL (IV form) and from RoActemra? 162 mg (0.9 mL solution pre-filled syringe, subcutaneous(SC) form), to evaluate the use of the latter for preparing clinical solutions required for IV administration, so that in a situation of shortage of the IV medicine, the SC form could be used to prepare the solutions for IV delivery of TCZ. It is important to remember that during the current pandemic all the medicines are used off-label, since none of them has yet been approved for the treatment of COVID-19.